Showing results (1-10 of 93) with videos related to
Sort By:
Pageof 10
Cancer Treatment Reports|May 1, 1985
Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formationR T Chlebowski, M Dietrich, S Akman, et al.Cancer Research|February 1, 1984
Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight lossR T Chlebowski, D Heber, B Richardson, et al.Cancer Treatment Reports|January 1, 1982
Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell lineR T Chlebowski, J B Block, D Cundiff, et al.Cancer Treatment Reports|April 1, 1984
Abnormal deoxyuridine suppression as a rapid predictor for antimetabolite chemosensitivity: correlation with in vitro tests of growth inhibitionJ B Block, R T Chlebowski, M F Dietrich, et al.Cancer|August 15, 1983
Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trialR T Chlebowski, R Pugh, J M Weiner, et al.Cancer Treatment Reports|March 1, 1984
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic resultsR T Chlebowski, A Brzechwa-Adjukiewicz, A Cowden, et al.American Journal of Clinical Oncology|April 1, 1985
Doxorubicin, cyclophosphamide, CCNU, and vincristine with or without cisplatinum in non-small cell lung cancerR T Chlebowski, J S Chlebowski, J Herrold, et al.Cancer Research|November 1, 1982
Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancerR T Chlebowski, C H Gota, K K Chan, et al.Hematology/Oncology Clinics of North America|February 1, 1991
Nutritional support of the medical oncology patientR T ChlebowskiSeminars in Oncology|September 7, 2001
Factors influencing the role of bisphosphonates in breast cancer managementR T ChlebowskiPageof 10